{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:11:09Z","timestamp":1792228269778,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40263-018-0530-8","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T02:56:02Z","timestamp":1529463362000},"page":"543-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis"],"prefix":"10.1007","volume":"32","author":[{"given":"Bernard M. J.","family":"Uitdehaag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","volume":"343","author":"C Confavreux","year":"2000","unstructured":"Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430\u20138.","journal-title":"N Engl J Med."},{"key":"530_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.clineuro.2005.11.018","volume":"108","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg. 2006;108:327\u201332.","journal-title":"Clin Neurol Neurosurg."},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","volume":"74","author":"H Tremlett","year":"2010","unstructured":"Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004\u201315.","journal-title":"Neurology."},{"key":"530_CR4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/NRE-131037","volume":"34","author":"O Ertekin","year":"2014","unstructured":"Ertekin O, Ozakbas S, Idiman E. Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis. NeuroRehabilitation. 2014;34:313\u201321.","journal-title":"NeuroRehabilitation."},{"key":"530_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1742395307087457","volume":"4","author":"G Green","year":"2008","unstructured":"Green G, Todd J. \u2018Restricting choices and limiting independence\u2019: social and economic impact of multiple sclerosis upon households by level of disability. Chronic Illn. 2008;4:160\u201372.","journal-title":"Chronic Illn."},{"key":"530_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3111\/13696990903543085","volume":"13","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010;13:78\u201389.","journal-title":"J Med Econ."},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336.","journal-title":"Mult Scler."},{"key":"530_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","volume":"28","author":"H Naci","year":"2010","unstructured":"Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28:363\u201379.","journal-title":"Pharmacoeconomics."},{"key":"530_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.msard.2015.09.002","volume":"6","author":"DS Goodin","year":"2016","unstructured":"Goodin DS, Reder AT, Bermel RA, et al. Relapses in multiple sclerosis: relationship to disability. Mult Scler Relat Disord. 2016;6:10\u201320.","journal-title":"Mult Scler Relat Disord."},{"key":"530_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","volume":"31","author":"CE Munster van","year":"2017","unstructured":"van Munster CE, Uitdehaag BM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31:217\u201336.","journal-title":"CNS Drugs."},{"key":"530_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000136645","volume":"31","author":"JF Kurtzke","year":"2008","unstructured":"Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008;31:1\u20139.","journal-title":"Neuroepidemiology."},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1756285610374117","volume":"3","author":"MD Goldman","year":"2010","unstructured":"Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010;3:229\u201339.","journal-title":"Ther Adv Neurol Disord."},{"key":"530_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrneurol.2017.171","volume":"14","author":"C Tur","year":"2018","unstructured":"Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14:75\u201393.","journal-title":"Nat Rev Neurol."},{"key":"530_CR14","unstructured":"Neurostatus.net. 2016. https:\/\/www.neurostatus.net\/index.php . Accessed Apr 2018."},{"key":"530_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","volume":"23","author":"RW Motl","year":"2017","unstructured":"Motl RW, Cohen JA, Benedict R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:704\u201310.","journal-title":"Mult Scler."},{"key":"530_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","volume":"23","author":"P Feys","year":"2017","unstructured":"Feys P, Lamers I, Francis G, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23:711\u201320.","journal-title":"Mult Scler."},{"key":"530_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871\u201382.","journal-title":"Brain."},{"issue":"Suppl 3","key":"530_CR18","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.0b013e3181dbb571","volume":"74","author":"CH Polman","year":"2010","unstructured":"Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010;74(Suppl 3):S8\u201315.","journal-title":"Neurology."},{"key":"530_CR19","first-page":"1319","volume":"57","author":"DM Miller","year":"2000","unstructured":"Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319\u201324.","journal-title":"Arch Neurol."},{"key":"530_CR20","first-page":"262350","volume":"2014","author":"AM Lavery","year":"2014","unstructured":"Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014;2014:262350.","journal-title":"Mult Scler Int."},{"key":"530_CR21","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268\u201376.","journal-title":"Neurology."},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1212\/01.wnl.0000200778.65597.ae","volume":"66","author":"RP Kinkel","year":"2006","unstructured":"Kinkel RP, Kollman C, O\u2019Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5\u00a0years after a first demyelinating event. Neurology. 2006;66:678\u201384.","journal-title":"Neurology."},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med."},{"key":"530_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med."},{"key":"530_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"FD Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327\u201340.","journal-title":"Ann Neurol."},{"key":"530_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u201356.","journal-title":"Lancet Neurol."},{"key":"530_CR27","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819\u201328.","journal-title":"Lancet."},{"key":"530_CR28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829\u201339.","journal-title":"Lancet."},{"key":"530_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000\u20139.","journal-title":"N Engl J Med."},{"key":"530_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773\u201383.","journal-title":"J Neurol."},{"key":"530_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247\u201356.","journal-title":"Lancet Neurol."},{"key":"530_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705\u201316.","journal-title":"Mult Scler."},{"key":"530_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657\u201365.","journal-title":"Lancet Neurol."},{"key":"530_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.23938","volume":"73","author":"O Khan","year":"2013","unstructured":"Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705\u201313.","journal-title":"Ann Neurol."},{"key":"530_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418\u201328.","journal-title":"N Engl J Med."},{"key":"530_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","volume":"72","author":"J Cohen","year":"2015","unstructured":"Cohen J, Belova A, Selmaj K, et al. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015;72:1433\u201341.","journal-title":"JAMA Neurol."},{"key":"530_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.22316","volume":"69","author":"G Comi","year":"2011","unstructured":"Comi G, Cohen JA, Arnold DL, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011;69:75\u201382.","journal-title":"Ann Neurol."},{"key":"530_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med."},{"key":"530_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","volume":"8","author":"P O\u2019Connor","year":"2009","unstructured":"O\u2019Connor P, Filippi M, Arnason B, et al. 250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20\u00a0mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889\u201397.","journal-title":"Lancet Neurol."},{"key":"530_CR40","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","volume":"352","author":"L Kappos","year":"1998","unstructured":"Kappos L, European Study Group on Interferon \u03b2-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491\u20137.","journal-title":"Lancet."},{"key":"530_CR41","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","volume":"54","author":"GP Rice","year":"2000","unstructured":"Rice GP, Filippi M, Comi G, Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology. 2000;54:1145\u201355.","journal-title":"Neurology."},{"key":"530_CR42","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","volume":"56","author":"SPECTRIMS Study Group","year":"2001","unstructured":"SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56:1496\u2013504.","journal-title":"Neurology."},{"key":"530_CR43","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1212\/WNL.59.5.679","volume":"59","author":"JA Cohen","year":"2002","unstructured":"Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679\u201387.","journal-title":"Neurology."},{"key":"530_CR44","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"HP Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018\u201325.","journal-title":"Lancet."},{"key":"530_CR45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","volume":"75","author":"O Andersen","year":"2004","unstructured":"Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:706\u201310.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"Suppl 2","key":"530_CR46","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/135245850000602S08","volume":"6","author":"OR Hommes","year":"2000","unstructured":"Hommes OR, Maas-Enriquez M. ESIMS\u2014an ongoing clinical trial in secondary progressive multiple sclerosis. Mult Scler. 2000;6(Suppl 2):S27\u201332.","journal-title":"Mult Scler."},{"key":"530_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"OR Hommes","year":"2004","unstructured":"Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364:1149\u201356.","journal-title":"Lancet."},{"key":"530_CR48","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","volume":"63","author":"H Panitch","year":"2004","unstructured":"Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788\u201395.","journal-title":"Neurology."},{"key":"530_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"JS Wolinsky","year":"2007","unstructured":"Wolinsky JS, Narayana PA, O\u2019Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14\u201324.","journal-title":"Ann Neurol."},{"key":"530_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/135245859700300217","volume":"3","author":"D Poehlau","year":"1997","unstructured":"Poehlau D, Federlein J, Postert T, et al. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis: outline of a double-blind randomized, placebo-controlled trial. Mult Scler. 1997;3:149\u201352.","journal-title":"Mult Scler."},{"key":"530_CR51","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/1352458507078400","volume":"13","author":"D P\u00f6hlau","year":"2007","unstructured":"P\u00f6hlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler. 2007;13:1107\u201317.","journal-title":"Mult Scler."},{"key":"530_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460\u201371.","journal-title":"Ann Neurol."},{"key":"530_CR53","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","volume":"77","author":"MS Freedman","year":"2011","unstructured":"Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011;77:1551\u201360.","journal-title":"Neurology."},{"key":"530_CR54","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075\u201384.","journal-title":"Lancet."},{"key":"530_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320.","journal-title":"N Engl J Med."},{"key":"530_CR56","doi-asserted-by":"publisher","first-page":"e0168834","DOI":"10.1371\/journal.pone.0168834","volume":"12","author":"B Brochet","year":"2017","unstructured":"Brochet B, Deloire MS, Perez P, et al. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS One. 2017;12:e0168834.","journal-title":"PLoS One."},{"key":"530_CR57","unstructured":"ClinicalTrials.gov. Effect of MD1003 in progressive multiple sclerosis (SPI2). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02936037?term=02936037&rank=1 . Accessed Aug 2017."},{"key":"530_CR58","unstructured":"ClinicalTrials.gov. Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01665144?term=01665144&rank=1 . Accessed Aug 2017."},{"key":"530_CR59","unstructured":"ClinicalTrials.gov. Effect of MD1003 in spinal progressive multiple sclerosis (MS-SPI). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02220933?term=02220933&rank=1 . Accessed Aug 2017."},{"key":"530_CR60","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1212\/WNL.51.5.1342","volume":"51","author":"JH Noseworthy","year":"1998","unstructured":"Noseworthy JH, O\u2019Brien P, Erickson BJ, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology. 1998;51:1342\u201352.","journal-title":"Neurology."},{"key":"530_CR61","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1212\/WNL.54.9.1726","volume":"54","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Wolinsky JS, Lublin FD, et al., and the North American Linomide Investigators. Linomide in relapsing and secondary progressive MS part I: trial design and clinical results. Neurology. 2000;54:1726\u201333.","journal-title":"Neurology."},{"key":"530_CR62","first-page":"189624","volume":"2013","author":"BC Healy","year":"2013","unstructured":"Healy BC, Engler D, Glanz B, et al. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int. 2013;2013:189624.","journal-title":"Mult Scler Int."},{"key":"530_CR63","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138:3287\u201398.","journal-title":"Brain."},{"key":"530_CR64","unstructured":"ClinicalTrials.gov. The efficacy, safety, and tolerability of laquinimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO). 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01707992?term=01707992&rank=1 . Accessed Jul 2017."},{"key":"530_CR65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.33588\/rn.5106.2010390","volume":"51","author":"D Cadavid","year":"2010","unstructured":"Cadavid D, Tang Y, O\u2019Neill G. Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol. 2010;51:321\u20139 (in Spanish).","journal-title":"Rev Neurol"},{"key":"530_CR66","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1212\/NXI.0000000000000358","volume":"4","author":"MW Koch","year":"2017","unstructured":"Koch MW, Cutter GR, Giovannoni G, et al. Comparative utility of disability progression measures in PPMS: analysis of the PROMiSe data set. Neurol Neuroimmunol Neuroinflamm. 2017;4:e358.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"530_CR67","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/03\/WC500185161.pdf . Accessed Jul 2017."},{"key":"530_CR68","unstructured":"LaRocca NG, Hudson LD, Rudick R, et al. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Mult Scler. 2017:1352458517723718."},{"key":"530_CR69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1352458513503392","volume":"20","author":"RA Rudick","year":"2014","unstructured":"Rudick RA, Larocca N, Hudson LD. Multiple Sclerosis Outcome Assessments Consortium: genesis and initial project plan. Mult Scler. 2014;20:12\u20137.","journal-title":"Mult Scler."},{"key":"530_CR70","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1080\/03007995.2016.1222516","volume":"32","author":"A Bin Sawad","year":"2016","unstructured":"Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, et al. Evaluation of the Expanded Disability Status Scale and the multiple sclerosis functional composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses. Curr Med Res Opin. 2016;32:1969\u201374.","journal-title":"Curr Med Res Opin."},{"key":"530_CR71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","volume":"23","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23:94\u2013105.","journal-title":"Mult Scler."},{"key":"530_CR72","doi-asserted-by":"crossref","unstructured":"Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2017:1352458517709619.","DOI":"10.1177\/1352458517709619"},{"issue":"9","key":"530_CR73","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrd.2017.115","volume":"16","author":"JR Plemel","year":"2017","unstructured":"Plemel JR, Liu WQ, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nat Rev Drug Discov. 2017;16(9):617\u201334.","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"530_CR74","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s13311-017-0558-3","volume":"14","author":"MP Sormani","year":"2017","unstructured":"Sormani MP, Pardini M. Assessing repair in multiple sclerosis: outcomes for phase II clinical trials. Neurotherapeutics. 2017;14(4):924\u201333.","journal-title":"Neurotherapeutics."},{"key":"530_CR75","doi-asserted-by":"publisher","first-page":"e0154335","DOI":"10.1371\/journal.pone.0154335","volume":"11","author":"VA Block","year":"2016","unstructured":"Block VA, Pitsch E, Tahir P, et al. Remote physical activity monitoring in neurological disease: a systematic review. PLoS One. 2016;11:e0154335.","journal-title":"PLoS One."},{"key":"530_CR76","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00415-016-8334-6","volume":"264","author":"VJ Block","year":"2017","unstructured":"Block VJ, Lizee A, Crabtree-Hartman E, et al. Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. 2017;264:316\u201326.","journal-title":"J Neurol."},{"key":"530_CR77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijmedinf.2017.01.006","volume":"100","author":"MM Engelhard","year":"2017","unstructured":"Engelhard MM, Patek SD, Sheridan K, et al. Remotely engaged: Lessons from remote monitoring in multiple sclerosis. Int J Med Inform. 2017;100:26\u201331.","journal-title":"Int J Med Inform."},{"key":"530_CR78","first-page":"10","volume":"1","author":"MF George","year":"2016","unstructured":"George MF, Holingue CB, Briggs FB, et al. Feasibility study for remote assessment of cognitive function in multiple sclerosis. J Neurol Neuromed. 2016;1:10\u20138.","journal-title":"J Neurol Neuromed."},{"key":"530_CR79","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1177\/1352458514559296","volume":"21","author":"JR Settle","year":"2015","unstructured":"Settle JR, Robinson SA, Kane R, et al. Remote cognitive assessments for patients with multiple sclerosis: a feasibility study. Mult Scler. 2015;21:1072\u20139.","journal-title":"Mult Scler."},{"key":"530_CR80","unstructured":"National Multiple Sclerosis Society. National MS Society-supported collaborators publish reviews of tools used to measure MS progression. 2017. https:\/\/www.nationalmssociety.org\/About-the-Society\/News\/National-MS-Society-Supported-Collaborators-Publis . Accessed Jun 2017."},{"key":"530_CR81","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2017","unstructured":"Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:734\u201347.","journal-title":"Mult Scler."},{"key":"530_CR82","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721\u201333.","journal-title":"Mult Scler."},{"key":"530_CR83","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1177\/1352458517729465","volume":"23","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Cohen JA, Amato MP. Clinical outcome measures for progressive MS trials. Mult Scler. 2017;23:1627\u201335.","journal-title":"Mult Scler."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0530-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:30:35Z","timestamp":1751682635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0530-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0530-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"20 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nicky French, PhD, of Anthemis Consulting Ltd provided editorial support, funded by Teva Pharmaceutical Industries, Frazer, PA, USA. Teva provided a single medical-accuracy review of the final draft. The author was not compensated and retained full editorial control over the content of the paper. Open access was funded by VU University Medical Center, as part of the Springer Compact agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author has received consultancy fees from Genzyme, Biogen Idec, Teva, Merck Serono and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}